Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minimal disease activity treatment strategies in psoriatic arthritis
ISRCTN76054545Phase 4Completed
- Sponsor
- Erasmus MC
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of secukinumab, methotrexate, 5-aminosalicylic acid + sulphasalazine, triamcinolone and apremilast in psoriatic arthritis (PsA) (2 arms), sponsored by Erasmus MC. Primary endpoint: ACR50 at 6 months. Started Dec 2019; status: completed.
02
Drugs
secukinumabmethotrexate5-aminosalicylic acid + sulphasalazinetriamcinoloneapremilast
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on ISRCTN76054545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN76054545.